Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30).
暂无分享,去创建一个
S. Burgess | J. Young | M. Parcells | L. Lee | B. Baaten | C. Tregaskes | L. Hunt | T. Davison | S C Burgess | J R Young | B J G Baaten | L Hunt | L N J Ross | M S Parcells | P M Kumar | C A Tregaskes | L F Lee | T F Davison | L. Ross | P. M. Kumar | Shane C. Burgess | L. F. Lee | John R. Young | Lawrence G. Hunt | Pankaj Kumar
[1] Kanji Hirai,et al. Marek’s Disease , 2001, Current Topics in Microbiology and Immunology.
[2] E. Kieff,et al. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[3] T. Werner,et al. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. , 1995, Nucleic acids research.
[4] G. Evan,et al. Cancer‐A matter of life and cell death , 1997, International journal of cancer.
[5] Toshiki Watanabe,et al. Hodgkin’s Lymphoma and CD30 Signal Transduction , 2003, International journal of hematology.
[6] S. Romagnani. Biology of human TH1 and TH2 cells , 1995, Journal of Clinical Immunology.
[7] Nancy F. Hansen,et al. Comparative analyses of multi-species sequences from targeted genomic regions , 2003, Nature.
[8] Toshiki Watanabe,et al. CD30: expression and function in health and disease. , 1998, Seminars in immunology.
[9] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[10] H. Skelton,et al. A clonal cutaneous CD30+ lymphoproliferative eruption in a patient with evidence of past exposure to hepatitis E , 2000, International journal of dermatology.
[11] S. Burgess,et al. Resistance to Marek's Disease Herpesvirus-induced Lymphoma is Multiphasic and Dependent on Host Genotype , 2001, Veterinary pathology.
[12] A. Houghton,et al. Immunity against cancer: lessons learned from melanoma. , 2001, Current opinion in immunology.
[13] T. Yoshino,et al. Antisense oligodeoxynucleotides to latent membrane protein 1 induce growth inhibition, apoptosis and Bcl‐2 suppression in Epstein‐Barr virus (EBV)‐transformed B‐lymphoblastoid cells, but not in EBV‐positive natural killer cell lymphoma cells , 2001, British journal of haematology.
[14] E. Coligan. Current protocols in immunology , 1991 .
[15] E. Podack,et al. CD30—Governor of Memory T Cells? , 2002, Annals of the New York Academy of Sciences.
[16] Y. Seko,et al. Expression of tumour necrosis factor (TNF) ligand superfamily co‐stimulatory molecules CD30L, CD27L, OX40L, and 4‐1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3 , 2001, The Journal of pathology.
[17] Shane C. Burgess,et al. Identification of the Neoplastically Transformed Cells in Marek's Disease Herpesvirus-Induced Lymphomas: Recognition by the Monoclonal Antibody AV37 , 2002, Journal of Virology.
[18] Titcomb Cp. Non-Hodgkin's lymphoma: in a class all its own. , 2001 .
[19] K. Schat,et al. Syngeneic Marek's disease virus (MDV)-specific cell-mediated immune responses against immediate early, late, and unique MDV proteins. , 1996, Virology.
[20] N. Meyers,et al. H = W. , 1964, Proceedings of the National Academy of Sciences of the United States of America.
[21] G. Inghirami,et al. CD30 in normal and neoplastic cells. , 1999, Clinical immunology.
[22] J. Lambert,et al. CD30‐Positive Anaplastic Large Cell Lymphoma (ALCL) of T‐Cell Lineage in a 14‐Month‐Old Infant With Perinatally Acquired HIV‐1 Infection , 1998, Journal of pediatric hematology/oncology.
[23] A. Krafft,et al. Primary effusion lymphoma with herpesvirus 8 DNA in patients coinfected with HIV and hepatitis C virus: a report of 2 cases. , 2001, The AIDS reader.
[24] Y. Sasaguri,et al. Adult T-cell leukemia/lymphoma in which the pathohistological diagnosis was identical to that of Ki-1 positive anaplastic large cell lymphoma. , 1999, Internal medicine.
[25] G. Pizzolo,et al. Peripheral T lymphocyte cytokine profile (IFNgamma, IL-2, IL-4) and CD30 expression/release during measles infection. , 1999, Haematologica.
[26] J. Panus,et al. Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: A soluble, secreted CD30 homologue , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[27] M. Sandberg,et al. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3 , 1997, Journal of virology.
[28] R. Witter,et al. Demonstration of a tumor-associated surface antigen in Marek's disease. , 1975, Journal of immunology.
[29] Daniel Schumacher,et al. Generation of a permanent cell line that supports efficient growth of Marek's disease virus (MDV) by constitutive expression of MDV glycoprotein E. , 2002, The Journal of general virology.
[30] E. Kieff,et al. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[31] H. Stein,et al. Structure of the Hodgkin's lymphoma-associated human CD30 gene and the influence of a microsatellite region on its expression in CD30(+) cell lines. , 2001, Biochimica et biophysica acta.
[32] L. Fugger,et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[33] P. Vandenabeele,et al. TTRAP, a Novel Protein That Associates with CD40, Tumor Necrosis Factor (TNF) Receptor-75 and TNF Receptor-associated Factors (TRAFs), and That Inhibits Nuclear Factor-κB Activation* , 2000, The Journal of Biological Chemistry.
[34] M. Tarkowski. Expression and function of CD30 on T lymphocytes. , 1999, Archivum immunologiae et therapiae experimentalis.
[35] Niels Grabe,et al. AliBaba2: Context specific identification of transcription factor binding sites , 2000, Silico Biol..
[36] A. Kutlar,et al. Hb Hammersmith [β 42(CD1) Phe→Ser]: Occurrence as a De Novo Mutation in Black Monozygotic Twins With Multiple Congenital Anomalies , 1998 .
[37] J. Young,et al. A chicken homologue of the co-stimulating molecule CD80 which binds to mammalian CTLA-4 , 1999, Immunogenetics.
[38] E. Kieff,et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation , 1996, Molecular and cellular biology.
[39] S. Burgess,et al. Marek's disease virus EcoRI-Q gene (meq) and a small RNA antisense to ICP4 are abundantly expressed in CD4+ cells and cells carrying a novel lymphoid marker, AV37, in Marek's disease lymphomas. , 1997, The Journal of general virology.
[40] A. Órfão,et al. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. , 2001, Cytometry.
[41] K. Nazerian. An updated list of avian cell lines and transplantable tumours. , 1987, Avian pathology : journal of the W.V.P.A.
[42] M. Takeshita. CD30-positive anaplastic large cell lymphoma with HTLV-I proviral integration: a unique histologic subgroup of adult T-cell leukemia/lymphoma. , 1999, Internal medicine.